Skip to Content

Lifecore Biomedical, Inc.

Securities Class Action

  • Date:
  • 9/27/2024
  • Company Name:
  • Lifecore Biomedical, Inc.
  • Stock Symbol:
  • LFCR
  • Class Period:
  • FROM 10/7/2020 TO 3/19/2024
  • Status:
  • Filed
  • Filing Date:
  • 7/29/2024
  • Court:
  • U.S. District Court: Minnesota

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) in the United States District Court for the District of Minnesota on behalf of all persons and entities who purchased or otherwise acquired Lifecore securities between October 7, 2020 and March 19, 2024, both dates inclusive (the “Class Period”). Investors have until September 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Between September 2022 and February 2024, Lifecore’s share price declined in response to a series of disclosures concerning material weaknesses in internal control over financial reporting, and delays in making required filings with the U.S. Securities and Exchange Commission (SEC).
 
The lawsuit alleges that (i) Lifecore maintained deficient internal controls over financial reporting; (ii) as a result, the Company issued several financial statements that were inaccurate and would need to be restated; (iii) Lifecore’s purported remediation efforts with respect to the foregoing deficiencies were ineffective; (iv) all of the foregoing impaired Lifecore’s ability to timely file periodic reports with the SEC in compliance with NASDAQ listing requirements; and (v) accordingly, the Company’s financial position and/or prospects were materially overstated.
 
If you purchased or otherwise acquired Lifecore shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Lifecore Biomedical. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: